Evaluation of PSA Antibody on E9802: Confirmation and Concordance

Trial Profile

Evaluation of PSA Antibody on E9802: Confirmation and Concordance

Completed
Phase of Trial: Phase II

Latest Information Update: 23 May 2017

At a glance

  • Drugs Rilimogene galvacirepvec (Primary) ; Rilimogene glafolivec (Primary) ; Sargramostim
  • Indications Prostate cancer
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 16 May 2017 Status changed from not yet recruiting to completed.
    • 13 Oct 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top